SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Cancer Biotech Apellis Pharma Sets Terms for $150M IPO October 30, 2017 Shakeup at Intrexon as a Subsidiary is Created and an Ex-Pfizer Exec Exits in Reorg March 12, 2017 Iconic Sues NantHealth's Over Altor BioScience Stock Fraud October 1, 2017
